OBJECTIVE: To examine the type specific seroprevalence of herpes simplex virus (HSV) types 1 and 2 infections, stratified by age and gender, and associated risk factors for HSV-2 seropositivity in Poland. METHODS: 2257 serum samples of individuals from 15-65 years were randomly selected from serum banks in four different geographical regions of Poland, including the Zachodnio-pomorskie, Warmińsko-mazurskie, Lubelskie, and Mazowieckie districts. Type specific serum antibodies to HSV-1 and HSV-2 were detected using HerpeSelect IgG ELISA tests. RESULTS: Overall prevalences of type specific HSV-1 and HSV-2 serum antibodies were 90.4% and 9.3%, respectively. Age standardised HSV-2 seroprevalence was higher in women (9.7%) than men (8.8%) (p = 0.06), and increased notably with age from 4% in 15-24 year olds to 12% in those aged 50-65 years. HSV-1 seroprevalence was consistently higher than HSV-2 seroprevalence in each specific age group, ranging from 74.5% in 15-24 year olds to 98.8% in 50-65 year olds. HSV-2 seroprevalence varied significantly by geographical region, with the highest prevalence in the Zachodnio-pomorskie district (12%). Significant multivariate risk factors for HSV-2 seropositivity included older age, female gender, and geographical place of residence. CONCLUSION: This large survey found a notably high seroprevalence of HSV-1, even among young female adolescents 15-19 years of age (80%). HSV-2 seropositivity was under 12% in all age groups surveyed in Poland, tending to be among the lowest overall HSV-2 seropositivity rates reported thus far in Europe.
OBJECTIVE: To examine the type specific seroprevalence of herpes simplex virus (HSV) types 1 and 2 infections, stratified by age and gender, and associated risk factors for HSV-2 seropositivity in Poland. METHODS: 2257 serum samples of individuals from 15-65 years were randomly selected from serum banks in four different geographical regions of Poland, including the Zachodnio-pomorskie, Warmińsko-mazurskie, Lubelskie, and Mazowieckie districts. Type specific serum antibodies to HSV-1 and HSV-2 were detected using HerpeSelect IgG ELISA tests. RESULTS: Overall prevalences of type specific HSV-1 and HSV-2 serum antibodies were 90.4% and 9.3%, respectively. Age standardised HSV-2 seroprevalence was higher in women (9.7%) than men (8.8%) (p = 0.06), and increased notably with age from 4% in 15-24 year olds to 12% in those aged 50-65 years. HSV-1 seroprevalence was consistently higher than HSV-2 seroprevalence in each specific age group, ranging from 74.5% in 15-24 year olds to 98.8% in 50-65 year olds. HSV-2 seroprevalence varied significantly by geographical region, with the highest prevalence in the Zachodnio-pomorskie district (12%). Significant multivariate risk factors for HSV-2 seropositivity included older age, female gender, and geographical place of residence. CONCLUSION: This large survey found a notably high seroprevalence of HSV-1, even among young female adolescents 15-19 years of age (80%). HSV-2 seropositivity was under 12% in all age groups surveyed in Poland, tending to be among the lowest overall HSV-2 seropositivity rates reported thus far in Europe.
Authors: P Wutzler; H W Doerr; I Färber; U Eichhorn; B Helbig; A Sauerbrei; A Brandstädt; H F Rabenau Journal: J Med Virol Date: 2000-06 Impact factor: 2.327
Authors: Lawrence R Stanberry; Spotswood L Spruance; Anthony L Cunningham; David I Bernstein; Adrian Mindel; Stephen Sacks; Stephen Tyring; Fred Y Aoki; Moncef Slaoui; Martine Denis; Pierre Vandepapeliere; Gary Dubin Journal: N Engl J Med Date: 2002-11-21 Impact factor: 91.245
Authors: R G Pebody; N Andrews; D Brown; R Gopal; H De Melker; G François; N Gatcheva; W Hellenbrand; S Jokinen; I Klavs; M Kojouharova; T Kortbeek; B Kriz; K Prosenc; K Roubalova; P Teocharov; W Thierfelder; M Valle; P Van Damme; R Vranckx Journal: Sex Transm Infect Date: 2004-06 Impact factor: 3.519
Authors: Edith Nakku-Joloba; Fred Kambugu; Julius Wasubire; Joshua Kimeze; Robert Salata; Jeffrey M Albert; Alfred Rimm; Christopher Whalen Journal: Afr Health Sci Date: 2014-12 Impact factor: 0.927
Authors: Gerhard Falkenhorst; Jacob Simonsen; Tina H Ceper; Wilfrid van Pelt; Henriette de Valk; Malgorzata Sadkowska-Todys; Lavinia Zota; Markku Kuusi; Cecilia Jernberg; Maria Cristina Rota; Yvonne Thp van Duynhoven; Peter Fm Teunis; Karen A Krogfelt; Kåre Mølbak Journal: BMC Public Health Date: 2012-07-16 Impact factor: 3.295